Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Nov 23;11(12):1686.
doi: 10.3390/antibiotics11121686.

Successful Treatment of Aortic Endocarditis by Achromobacter xylosoxidans with Cefiderocol Combination Therapy in a Non-Hodgkin Lymphoma Patient: Case Report and Literature Review

Gianfranco La Bella  1   2 , Francesco Salvato  1 , Graziano Antonio Minafra  3 , Irene Francesca Bottalico  3 , Tiziana Rollo  3 , Lucia Barbera  3 , Samantha De Tullio  3 , Gaetano Corso  1   3 , Sergio Lo Caputo  3   4 , Rosella De Nittis  3 , Fabio Arena  1   3
Affiliations
Review

Successful Treatment of Aortic Endocarditis by Achromobacter xylosoxidans with Cefiderocol Combination Therapy in a Non-Hodgkin Lymphoma Patient: Case Report and Literature Review

Gianfranco La Bella et al. Antibiotics (Basel). .

Abstract

Achromobacter xylosoxidans is a Gram-negative aerobic opportunistic bacterium, belonging to the order of Burkholderiales, that can cause infections of virtually all body districts in patients with underlying diseases. However, A. xylosoxidans has rarely been associated with infective endocarditis. The treatment of A. xylosoxidans infections is complicated by both intrinsic and acquired resistance. Here we report on a case of aortic endocarditis by A. xylosoxidans in a Non-Hodgkin lymphoma patient treated with a combination of cefiderocol and other antibiotics, and summarize the available literature.

Keywords: Gram-negative; bloodstream infections; cephalosporins; multi-drug resistance; siderophore.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Summary of the therapeutic regimen and bacteriological tests carried out during the infectious diseases ward stay. N.A.: no activity; MEM: meropenem; FOS: Fosfomycin; TMP-SXT: trimethoprim-sulfamethoxazole; FDC: cefiderocol.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Isler B., Kidd T.J., Stewart A.G., Harris P., Paterson D.L. Achromobacter infections and treatment options. Antimicrob. Agents Chemother. 2020;64:e01025-20. doi: 10.1128/AAC.01025-20. - DOI - PMC - PubMed
    1. Kengni Tameze J., Korpak K., Compagnie M., Levie H., Cherifi S., Lali S.E. Mitral endocarditis caused by Achromobacter xylosoxidans in an older patient: Case report and literature review. IDCases. 2022;27:e01421. doi: 10.1016/j.idcr.2022.e01421. - DOI - PMC - PubMed
    1. EUCAST. [(accessed on 18 August 2022)]. Available online: https://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Expert_Rule....
    1. Abbott I.J., Peleg A.Y. Stenotrophomonas, Achromobacter, and nonmelioid Burkholderia species: Antimicrobial resistance and therapeutic strategies. Semin. Respir. Crit. Care Med. 2015;36:99–110. - PubMed
    1. Trancassini M., Iebba V., Citerà N., Tuccio V., Magni A., Varesi P., De Biase R.V., Totino V., Santangelo F., Gagliardi A., et al. Outbreak of Achromobacter xylosoxidans in an Italian cystic fibrosis center: Genome variability, biofilm production, antibiotic resistance, and motility in isolated strains. Front. Microbiol. 2014;5:138. doi: 10.3389/fmicb.2014.00138. - DOI - PMC - PubMed

LinkOut - more resources